GeneBioTech Co. Ltd
Genebiotech Co., Ltd., a specialized fermentation company, researches, develops, produces, and sells biological resources for use in animal resources, agriculture, food, medicine, etc. It offers functional feed ingredients and additives, as well as veterinary medicines. The company was founded in 1984 and is headquartered in Gongju, South Korea.
GeneBioTech Co. Ltd (086060) - Net Assets
Latest net assets as of September 2025: ₩54.03 Billion KRW
Based on the latest financial reports, GeneBioTech Co. Ltd (086060) has net assets worth ₩54.03 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩75.43 Billion) and total liabilities (₩21.41 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩54.03 Billion |
| % of Total Assets | 71.62% |
| Annual Growth Rate | 7.15% |
| 5-Year Change | 13.16% |
| 10-Year Change | 76.76% |
| Growth Volatility | 10.24 |
GeneBioTech Co. Ltd - Net Assets Trend (2009–2024)
This chart illustrates how GeneBioTech Co. Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for GeneBioTech Co. Ltd (2009–2024)
The table below shows the annual net assets of GeneBioTech Co. Ltd from 2009 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩50.97 Billion | +5.52% |
| 2023-12-31 | ₩48.30 Billion | +5.64% |
| 2022-12-31 | ₩45.73 Billion | +4.05% |
| 2021-12-31 | ₩43.95 Billion | -2.44% |
| 2020-12-31 | ₩45.04 Billion | -4.02% |
| 2019-12-31 | ₩46.93 Billion | -2.16% |
| 2018-12-31 | ₩47.96 Billion | +18.46% |
| 2017-12-31 | ₩40.49 Billion | +3.76% |
| 2016-12-31 | ₩39.02 Billion | +35.32% |
| 2015-12-31 | ₩28.84 Billion | +23.13% |
| 2014-12-31 | ₩23.42 Billion | +1.39% |
| 2013-12-31 | ₩23.10 Billion | +8.58% |
| 2012-12-31 | ₩21.27 Billion | +9.21% |
| 2011-12-31 | ₩19.48 Billion | +6.00% |
| 2010-12-31 | ₩18.38 Billion | +1.64% |
| 2009-12-31 | ₩18.08 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to GeneBioTech Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 3180259892000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩31.80 Billion | 62.39% |
| Common Stock | ₩4.31 Billion | 8.45% |
| Other Components | ₩14.86 Billion | 29.16% |
| Total Equity | ₩50.97 Billion | 100.00% |
GeneBioTech Co. Ltd Competitors by Market Cap
The table below lists competitors of GeneBioTech Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
BBIA Co., Ltd.
KQ:451250
|
$21.55 Million |
|
Pioneer Bankshares Inc
PINK:PNBI
|
$21.56 Million |
|
Voltaic Minerals Corp
V:VLT
|
$21.56 Million |
|
China HK Power Smart Energy Group Limited
OTCGREY:CHNTF
|
$21.56 Million |
|
Anli International Co Ltd
TWO:5223
|
$21.55 Million |
|
Wotso
AU:WOT
|
$21.55 Million |
|
Habco Trans Maritima
JK:HATM
|
$21.55 Million |
|
Earlyworks Co., Ltd. American Depositary Shares
NASDAQ:ELWS
|
$21.54 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in GeneBioTech Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 48,304,747,590 to 50,972,317,840, a change of 2,667,570,250 (5.5%).
- Net income of 2,865,233,580 contributed positively to equity growth.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩2.87 Billion | +5.62% |
| Other Changes | ₩-197.66 Million | -0.39% |
| Total Change | ₩- | 5.52% |
Book Value vs Market Value Analysis
This analysis compares GeneBioTech Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.88x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.14x to 0.88x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩4531.87 | ₩5180.00 | x |
| 2017-12-31 | ₩4702.18 | ₩5180.00 | x |
| 2018-12-31 | ₩5570.29 | ₩5180.00 | x |
| 2019-12-31 | ₩5450.16 | ₩5180.00 | x |
| 2020-12-31 | ₩5231.12 | ₩5180.00 | x |
| 2021-12-31 | ₩5103.62 | ₩5180.00 | x |
| 2022-12-31 | ₩5310.44 | ₩5180.00 | x |
| 2023-12-31 | ₩5609.93 | ₩5180.00 | x |
| 2024-12-31 | ₩5919.72 | ₩5180.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently GeneBioTech Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 5.62%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.45%
- • Asset Turnover: 1.15x
- • Equity Multiplier: 1.41x
- Recent ROE (5.62%) is above the historical average (3.39%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | 3.96% | 4.08% | 0.59x | 1.63x | ₩-1.09 Billion |
| 2010 | 5.68% | 5.67% | 0.64x | 1.58x | ₩-809.52 Million |
| 2011 | 2.72% | 1.89% | 0.63x | 2.30x | ₩-1.46 Billion |
| 2012 | 2.95% | 1.02% | 1.29x | 2.26x | ₩-1.43 Billion |
| 2013 | 0.88% | 0.37% | 1.14x | 2.09x | ₩-2.11 Billion |
| 2014 | 4.47% | 2.11% | 1.09x | 1.94x | ₩-1.35 Billion |
| 2015 | 5.94% | 3.28% | 1.06x | 1.71x | ₩-1.17 Billion |
| 2016 | 7.01% | 4.91% | 0.94x | 1.52x | ₩-1.17 Billion |
| 2017 | 5.16% | 3.76% | 0.93x | 1.47x | ₩-1.96 Billion |
| 2018 | 5.59% | 4.27% | 0.86x | 1.51x | ₩-2.11 Billion |
| 2019 | 1.80% | 1.45% | 0.86x | 1.45x | ₩-3.85 Billion |
| 2020 | -5.20% | -3.96% | 0.95x | 1.38x | ₩-6.85 Billion |
| 2021 | -1.10% | -0.77% | 1.04x | 1.37x | ₩-4.88 Billion |
| 2022 | 3.33% | 1.84% | 1.29x | 1.40x | ₩-3.05 Billion |
| 2023 | 5.36% | 3.26% | 1.20x | 1.37x | ₩-2.24 Billion |
| 2024 | 5.62% | 3.45% | 1.15x | 1.41x | ₩-2.23 Billion |
Industry Comparison
This section compares GeneBioTech Co. Ltd's net assets metrics with peer companies in the Pharmaceuticals industry.
Industry Context
- Industry: Pharmaceuticals
- Average net assets among peers: $96,196,506,488
- Average return on equity (ROE) among peers: -9.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| GeneBioTech Co. Ltd (086060) | ₩54.03 Billion | 3.96% | 0.40x | $21.55 Million |
| Sam Chun Dang Pharm. Co. Ltd (000250) | $114.32 Billion | 10.17% | 0.61x | $3.69 Billion |
| DongKoo Bio&Pharma Co. Ltd (006620) | $94.65 Billion | 9.66% | 0.53x | $57.77 Million |
| NatureCell Co.Ltd (007390) | $34.02 Billion | -9.48% | 0.55x | $37.82 Million |
| Sam-A Pharm. Co. Ltd (009300) | $148.92 Billion | 6.63% | 0.09x | $21.27 Million |
| Kyung Dong Pharmaceutical Co. Ltd (011040) | $257.20 Billion | 4.73% | 0.21x | $50.06 Million |
| WooGene B&G Co. Ltd (018620) | $26.51 Billion | -25.02% | 1.26x | $10.61 Million |
| Oscotec Inc (039200) | $28.83 Billion | -91.10% | 0.70x | $890.75 Million |
| EstechPharma Co. Ltd (041910) | $123.30 Billion | 5.58% | 0.09x | $50.99 Million |
| Komipharm International Co. Ltd (041960) | $93.39 Billion | -15.32% | 0.50x | $237.27 Million |
| Eagle Veterinary Technology Co.Ltd (044960) | $40.83 Billion | 8.91% | 0.29x | $20.48 Million |